Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07281391 · ClinicalTrials.gov registry record
IOP Reduction in Pigmentary Glaucoma Using DSLT
A clinical trial, sponsored by Mann Eye Institute.
- Recruiting
- Registry status
- 45
- Enrollment target
NCT07281391: Recruiting study, sponsored by Mann Eye Institute.
NCT07281391 is a clinical trial that is actively recruiting participants, run by Mann Eye Institute. The registered enrollment target is 45 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07281391 is actively recruiting participants, sponsored by Mann Eye Institute.
- RECRUITING
- Registry status
- 45 participants
- Enrollment target
Study Summary
This study is a single-site, single-arm, prospective, observational study of IOP reduction after DSLT. Subjects will be assessed up to 12 months post-operatively. Clinical evaluations will include IOP and number of glaucoma medications.
Interventions
- DEVICE Voyager DSLT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2026-03-19 |
| Est. Completion | 2027-04-01 |
What NCT07281391 shows while recruiting
NCT07281391 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 45 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Voyager DSLT is the first listed.
NCT07281391 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07281391 about?
NCT07281391 is a clinical study titled "IOP Reduction in Pigmentary Glaucoma Using DSLT". This study is a single-site, single-arm, prospective, observational study of IOP reduction after DSLT. Subjects will be assessed up to 12 months post-operatively. Clinical evaluations will include IOP and number of glaucoma medications.
What is the current status of trial NCT07281391?
This trial is currently recruiting. The enrollment target is 45 participants. The study started on 2026-03-19. Estimated completion is 2027-04-01.
What interventions are being tested in trial NCT07281391?
The interventions under investigation include: Voyager DSLT (DEVICE).
Who is sponsoring clinical trial NCT07281391?
This trial is sponsored by Mann Eye Institute, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI